NDAORALPOWDER
Approved
Dec 2013
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
KUVAN (sapropterin dihydrochloride) by BioMarin Pharmaceutical is bh4, the cofactor for the enzyme phenylalanine hydroxylase (pah). Approved for phenylketonuria. First approved in 2013.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KUVAN (sapropterin dihydrochloride) is an oral powder formulation that acts as a synthetic form of tetrahydrobiopterin (BH4), a cofactor for phenylalanine hydroxylase (PAH). It is indicated to reduce blood phenylalanine levels in adults and children with BH4-responsive phenylketonuria (PKU) or hyperphenylalaninemia. The drug works by activating residual PAH enzyme activity to improve normal oxidative metabolism of phenylalanine.
$0.007BPart D
Peak7.0 years to LOEThe product is at peak lifecycle with modest Part D spending of $7M annually (426 claims in 2023), indicating a stable but niche market with limited team expansion opportunities.
Mechanism of Action
BH4, the cofactor for the enzyme phenylalanine hydroxylase (PAH). PAH hydroxylates Phe through an oxidative reaction to form tyrosine. In patients with PKU, PAH activity is absent or deficient. Treatment with BH4 can activate residual PAH enzyme activity, improve the normal oxidative metabolism of…
Indications (1)
Clinical Trials (20)
PD-1 Antibody and Sapropterin Dihydrochloride in Patients With PDAC
Started Apr 2024
20 enrolled
Pancreatic Adenocarcinoma Metastatic
The Effectiveness of Kuvan in Amish PKU Patients
Started Jan 2018
7 enrolled
Phenylketonuria
Retrospective Observational Safety Effectiveness With Kuvan in hpA
Started Oct 2017
26 enrolled
Tetrahydrobiopterin Deficiency
Kuvan®'s Effect on the Cognition of Children With Phenylketonuria
Started Oct 2013
34 enrolled
Phenylketonuria
Phase 3 Open-label Study to Evaluate the Response and Safety of Kuvan® in Subjects With Phenylketonuria
Started Nov 2012
90 enrolled
Phenylketonuria
Worked on KUVAN at BioMarin Pharmaceutical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.